benphothiamine has been researched along with Diabetes Mellitus, Type 2 in 14 studies
benfotiamine : A thioester that is a synthetic analogue of thiamine obtained by acylative cleavage of the thiazole ring and O-phospohorylation.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Currently, there are only few pathogenetically oriented pharmacotherapies for DSPN, one of which is benfotiamine, a prodrug of thiamine with a high bioavailability and favourable safety profile." | 3.11 | BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. ( Al-Hasani, H; Bönhof, GJ; Herder, C; Icks, A; Knebel, B; Kuss, O; Reule, C; Roden, M; Sipola, G; Strassburger, K; Strom, A; Wollmann, JC; Ziegler, D, 2022) |
| "In people with Type 2 diabetes and markedly impaired fasting flow-mediated dilatation, a mixed test meal does not further deteriorate flow-mediated dilatation or variables of microvascular or autonomic nervous function." | 2.78 | A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes. ( Pop, A; Stirban, A; Tschoepe, D, 2013) |
| "Patients with type 2 diabetes and urinary albumin excretion in the high-normal and microalbuminuric range (15-300 mg/24h) were randomized to receive benfotiamine (n = 39) or placebo (n = 43)." | 2.77 | Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. ( Alkhalaf, A; Bakker, SJ; Bilo, HJ; Gans, RO; Groenier, KH; Heeringa, P; Kleefstra, N; Navis, GJ; Schalkwijk, CG; Scheijen, JL, 2012) |
| "Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43)." | 2.75 | A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. ( Achenbach, U; Alkhalaf, A; Bakker, SJ; Bilo, HJ; Gans, RO; Kleefstra, N; Klooster, A; Mijnhout, GS; Navis, GJ; Slingerland, RJ; van Oeveren, W, 2010) |
| "165 patients with symmetrical, distal diabetic polyneuropathy were randomised to one of three treatment groups entering the wash-out phase and 133/124 patients were analysed in the ITT/PP analysis: Benfotiamine 600 mg per day (n=47/43), benfotiamine 300 mg per day (n=45/42) or placebo (n=41/39)." | 2.73 | Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. ( Achenbach, U; Bretzel, RG; Federlin, K; Gaus, W; Stracke, H, 2008) |
| "Thirteen people with type 2 diabetes were given a heat-processed test meal with a high AGE content (HAGE; 15." | 2.72 | Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. ( Gawlowski, T; Götting, C; Horstmann, T; Kleesiek, K; Koschinsky, T; Mueller-Roesel, M; Negrean, M; Stirban, A; Stratmann, B; Tschoepe, D; Uribarri, J; Vlassara, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bönhof, GJ | 1 |
| Sipola, G | 1 |
| Strom, A | 1 |
| Herder, C | 1 |
| Strassburger, K | 1 |
| Knebel, B | 1 |
| Reule, C | 1 |
| Wollmann, JC | 1 |
| Icks, A | 1 |
| Al-Hasani, H | 1 |
| Roden, M | 1 |
| Kuss, O | 1 |
| Ziegler, D | 1 |
| Stirban, A | 4 |
| Pop, A | 2 |
| Tschoepe, D | 4 |
| Fischer, A | 1 |
| Heckermann, S | 1 |
| Sergienko, VA | 1 |
| Segin, VB | 1 |
| Samir, A | 1 |
| Sergienko, AA | 1 |
| Alkhalaf, A | 2 |
| Klooster, A | 1 |
| van Oeveren, W | 1 |
| Achenbach, U | 2 |
| Kleefstra, N | 2 |
| Slingerland, RJ | 1 |
| Mijnhout, GS | 1 |
| Bilo, HJ | 2 |
| Gans, RO | 2 |
| Navis, GJ | 2 |
| Bakker, SJ | 2 |
| Groenier, KH | 1 |
| Heeringa, P | 1 |
| Scheijen, JL | 1 |
| Schalkwijk, CG | 2 |
| Engelen, L | 1 |
| Stehouwer, CD | 1 |
| Haupt, E | 1 |
| Ledermann, H | 1 |
| Köpcke, W | 1 |
| Negrean, M | 2 |
| Stratmann, B | 2 |
| Gawlowski, T | 1 |
| Horstmann, T | 1 |
| Götting, C | 2 |
| Kleesiek, K | 2 |
| Mueller-Roesel, M | 1 |
| Koschinsky, T | 1 |
| Uribarri, J | 1 |
| Vlassara, H | 1 |
| Jermendy, G | 1 |
| Salomon, J | 1 |
| Stracke, H | 1 |
| Gaus, W | 1 |
| Federlin, K | 1 |
| Bretzel, RG | 1 |
| Sadekov, RA | 1 |
| Danilov, AB | 1 |
| Veĭn, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy[NCT00565318] | Phase 4 | 86 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System[NCT00446810] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for benphothiamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2013 |
9 trials available for benphothiamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Humans; Polyneuropathies; Qua | 2022 |
A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes.
Topics: Adult; Aged; Antioxidants; Autonomic Pathways; Biomarkers; Blood Glucose; Cross-Over Studies; Diabet | 2013 |
Variability of skin autofluorescence measurement over 6 and 12 weeks and the influence of benfotiamine treatment.
Topics: Adult; Aged; Chelating Agents; Cross-Over Studies; Diabetes Complications; Diabetes Mellitus, Type 2 | 2013 |
A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.
Topics: Adjuvants, Immunologic; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotens | 2010 |
Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.
Topics: Aged; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endoth | 2012 |
Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study).
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 2005 |
Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes.
Topics: Adjuvants, Immunologic; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; En | 2006 |
Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study.
Topics: Adjuvants, Immunologic; Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic | 2008 |
[Diabetic polyneuropathy treatment by milgamma-100 preparation].
Topics: Adult; Chelating Agents; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination | 1998 |
4 other studies available for benphothiamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[The effect of long-chain polyunsaturated higher ω-3 fatty acids, benfotiamine and α-lipoic acid on the lipid metabolism in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy].
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; D | 2013 |
[Oral benfotiamine therapy. Thus you protect the nerves of diabetic patients].
Topics: Administration, Oral; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Melli | 2004 |
Evaluating thiamine deficiency in patients with diabetes.
Topics: Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Male; Mi | 2006 |
Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: an effect prevented by benfotiamine and cooking method.
Topics: Adiponectin; Analysis of Variance; Body Mass Index; Chelating Agents; Cooking; Diabetes Mellitus, Ty | 2007 |